China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical trial ethical approval in Australia to conduct a Phase I clinical study for its YBSW015, a bispecific neutralizing antibody against SARS-CoV-2 developed to treat COVID-19 infection.
Mechanism of Action
YBSW015 is a bispecific antibody (BsAb) targeting the S protein receptor binding domain (RBD) of SARS-CoV-2. It works by blocking different epitopes of the S protein RBD through antibody neutralization, thereby preventing the novel coronavirus from invading cells and blocking the virus invasion pathway. This innovative approach sets YBSW015 apart as there is no similar product available anywhere in the world.-Fineline Info & Tech
